30-Oct-2020 | Market Research Store
According to the U.S. Food and Drug Administration(FDA), recently, anovelmedicationhas been approved as a part of aninfluential and three-pronged treatment program for the deadliest strain of tuberculosis. The drug named Pretomanid in combination with linezolid and bedaquiline was sanctioned to be utilizedin adults havingXDR-TB, which is extensive multidrug-resistant tuberculosis,of the lungs. It is triggered by a bacterium that attacks the lungs. However there are other forms of TB that can also cause havoc invarious parts of the body including the spine, kidney, and brain.This FDA approved drug is likely to turn into a revolutionary in the research of tuberculosis. Furthermore, the drug showed 89% cure in the XDR-TBpatients.
However, it was observed that the new drug is not an easily consumable medication. The number of side effects caused by Pretomanid was quite high. That included anemia, nerve damage, acne, nausea, headache,increased liver enzymes,vomiting, increased pancreatic enzymes, low blood sugar, indigestion, rash, visual impairment, and diarrhea. In comparison to the disease, the adverse effects of treatment are far less.When the numbers are considered, the mortality rate caused due to TB across the globe is high. But the XDR-TB is found to affect very few of the 30,000 people across 100 nations.
Speaking about TB, researchers have lately started studyingresistant drugs to develop effective anti-TB drug. In July 2018, South Africa was the first-evernation to developa new anti-TB drug in its national program. This new drug—bedaquiline—is the first new anti-TB drug to be developed in the last four decades. It improves the survival ratein patients with multidrug resistant TB, possiblypresenting shorter treatment duration with fewer side effects.
Market Research Store has published a report on global tuberculosis diagnosis and treatment market. This report provides a holistic picture of the market dynamics, growth structure, market valuation, and future scope of the tuberculosis diagnosis and treatmentmarket.